Oncología (médica)

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Niraparib + TSR042 In BRCA Mutated Breast Cancer

   Rochester, Minn.

   The purpose of this study is to evaluate pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations. The drugs are Niraparib (Zejula) and Dostarlimab.

2. ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) (ACT-MBC)

   Rochester, Minn., Mankato, Minn., Eau Claire, Wis., Albert Lea, Minn.

   Collection of blood to track serial circulating tumor cells (CTCs) in subjects with metastatic breast cancer (MBC). Study will also collect data from investigators are Mayo Clinic and the Mayo Clinic Health Systems to determine effectiveness of the proposed process.

3. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this trial is to compare the usual treatment alone to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.

4. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

   Rochester, Minn.

   The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT).

   The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682.

5. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development

   Jacksonville, Fla.

   The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular involution status. 

6. Cutaneous Lymphoma Database

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

7. Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

   Jacksonville, Fla.

   The objective of this pilot stdy is to plan, develop and establish the acceptance and usability of a Point of Prostate Cancer Diagnosis (PPCD) iCCaRE Virtual Robot Assistant (ViRA).

   The specific aims of this study are to plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research, and to establish the acceptance and usability of the iCCaRE ViRA at a urology clinic among 50 Black men (BM).

8. A Study to Identify Late-Occurring Complications in Childhood Cancer Survivors

   Rochester, Minn.

   The purpose of this trial is to identify cancer survivors who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

9. A Study to Evaluate Chemotherapy-Induced Nausea in Breast Cancer Patients

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The long-term goal of this study is to alleviate the occurrence of CIN and fatigue and to improve chemotherapy treatment outcomes. The identification of associations between fatigue, CIN and chemotherapy-induced changes in gut microbiome composition profiles will increase our understanding of these mechanisms that underlie patient symptom experience. An increased understanding of the underlying mechanisms will provide targets for the development of novel interventions to help alleviate fatigue and CIN.

10. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

    Rochester, Minn.

    The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts.